We explored whether the administration of Lactobacillus fermentum CECT5716 could reduce the TLR2/TLR4 expression, inhibit the production of inflammatory factors by inflammatory cells, decrease intestinal leakage and pneumonia, and treat asthma. Here, TLR2 is linked to asthma.